Received: December 11, 2022 Accepted: December 13, 2022 Published: December 13, 2022
Hyperthyroidism is a dreadful clinical condition still vehemently present in today’s world with 1.3% of current population of human race fighting with it, female being more prone to it than males in a 5:1 ratio. It is a clinical condition where excessive thyroid hormones are produced by the thyroid gland; high T3, T4 and low TSH found in thyroid function test. This condition can be caused by many primary pathological condtions; Grave’s disease, thyroiditis, overactive nodule are some mention worthy reasons. The clinical manifestations are typical ones with problems like bradycardia, indigestion, diarrhoea, hyperkeratosis, loss of cognitive skills, menorrhagia, spontaneous abortion, erectile dysfunction in men, myopathy of proximal limb, pelvic and shoulder of muscles, Hoffman syndrome, Koch syndrome and many more. Over the time multiple treatment modalities of it has been utilized in clinical practice from Dunhill procedure thyrectomy, complete thyrectomy in surgical procedures to radio-iodine ablation and anti-thyroid drugs. The research and development in anti-thyroid drugs over the year has been significantly low. The drugs which are commonly utilized like carbimazole, methimazole, propylthiouracil, etc have been proven time and again to be highly fetotoxic with significantneuro- toxicity. Utilization of these drugs in pregnancy is no less than a nightmare both for the patient and the clinician. Hence, new anti-thyroid drugs are a necessity of the era. One such candidate has been developed by the presenter which has been provisionally patented and is under final judicial check-up now in the Indian patent office. The drug as has been chemically verified is stable with no fetotoxic or neurotoxic effects and has binding capacity with thyroid hormone receptors (THS), located in different part of the body. Hence might prove to be a candidate far better than present drugs in market and can become a game changer.